Effect of all-trans-retinoic acid on c-fms proto-oncogene [colony- stimulating factor 1 (CSF-1) receptor] expression and CSF-1-induced invasion and anchorage-independent growth of human breast carcinoma cells

Cancer Research

Volumn 59, Issue 21, 1999, Pages 5578-5585

  Sapi, Eva ^a   Flick, Maryann B ^a   Tartaro, Karrie ^a   Kim, Susan ^a   Rakhlin, Yelena ^a   Rodov, Sofya ^a   Kacinski, Barry M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR RECEPTOR; RECEPTOR BLOCKING AGENT; RETINOIC ACID; RETINOIC ACID RECEPTOR; TRANSCRIPTION FACTOR AP 1;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, NORTHERN; BREAST NEOPLASMS; CELL NUCLEUS; DEXAMETHASONE; DNA FOOTPRINTING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MUTATION; PLASMIDS; PROMOTER REGIONS (GENETICS); RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; TIME FACTORS; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0033229845     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Roberts, A. B., and Sporn, M. B. Cellular biology and biochemistry of the retinoids. In: M. B. Sporn, A. B. Roberts, and D. S. Goodman (eds.), The Retinoids, pp. 209-286 and 443-520. Orlando, FL: Academic Press, Inc., 1984.
2. Lotan, R. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim. Biophys. Acta, 605: 33-91, 1980.
3. Bollag, W., and Holdener, E. E. Retinoids in cancer prevention and therapy. Ann. Oncol., 3: 513-526, 1992.
4. Lacroix, A., and Lippman, M. E. Binding of retinoids to human breast cancer cells lines and their effects on cell growth. J. Clin. Invest., 65: 586-590, 1990.
5. Moon, R. C., and Mehta, R. G. Chemoprevention of experimental carcinogenesis in animals. Prev. Med., 18: 576-591, 1989.
6. Sheikh, M. S., Shao, Z., Chen, J., Hussain, A., Jetten, A. M., and Fontana, J. A. Estrogen receptor-negative breast carcinoma cells transfected with the estrogen receptor exhibit increased RARα gene expression and sensitivity to growth inhibition by retinoic acid. J. Cell. Biochem., 53: 394-404, 1993.
7. Modiano, M. R., Dalton, W. S., Lippman, S. M., Joffe, L., Booth, A. R., and Meyskens, F. L., Jr. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma. Invest. New Drugs, 8: 317-319, 1990.
8. Boccardo, F., Canobbio, L., Resasco, M., Decensi, A. U., Pastorino, G., and Brema, F. Phase II study of tamoxifen and high dose retinyl acetate in patients with advanced breast cancer. J. Cancer Res. Clin. Oncol., 116: 503-506, 1990.
9. Sutton, L., Warmuth, M., Petros, W., and Winer, E. Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a Phase II trial. Cancer Chemother. Pharmacol., 40: 335-341, 1997.
10. 3 receptor. Cell, 65: 1255-1266, 1991.
11. Li, J., Dong, Z., Dawson, M., and Colburn, N. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element. Cancer Res., 56: 483-489, 1996.
12. Huang, C., Ma, W., Dawson, M., Rincon, M., Flawell, R, and Dong, Z. Blocking activator protein-1 activity, but not activating retinoic acid response elements, is required for the antitumor promotion effects of retinoic acid. Proc. Natl. Acad. Sci. USA, 94: 5826-5830, 1997.
13. Dony, C., Kessel, M., and Gruss, P. Post-transcriptional control of myc and p53 expression during differentiation of the embryonal carcinoma cell line F9. Nature (Lond.), 317: 636-639, 1985.
14. Linardopoulos, S., Papadakis, E., Delakas, D., Theodosiou, V., Cranidis, A., and Spandidos, D. A. Human lung and bladder carcinoma tumors as compared to their adjacent normal tissue have elevated AP-1 activity associated with the retinoblastoma gene promoter. Anticancer Res., 13: 257-262, 1993.
15. Offterdinger, M., Schneider, S. M., Huber, H., and Grunt, T. W. Retinoids control the expression of c-erbB receptors in breast cancer cells. Biochem. Biophys. Res. Commun., 251: 907-913, 1998.
16. Shang, Y., Baumrucker, C. R., and Green, M. H. c-Myc is a major mediator of the synergistic growth inhibitory effects of retinoic acid and interferon in breast cancer cells. J. Biol. Chem., 273: 30608-30613, 1998.
17. Roman, S. D., Clarke, C. L., Hall, R. E., Alexander, I. E., and Sutherland, R. L. Expression and regulation of retinoic acid receptors in human breast cancer cells. Cancer Res., 52: 2236-2242, 1992.
18. Rishi, A. K., Gerald, T. M., Shao, Z. M., Li, X. S., Baumann, R. G., Dawson, M. I., and Fontana, J. A. Regulation of the human retinoic acid receptor a gene in the estrogen receptor negative human breast carcinoma cell lines SKBR-3 and MDA-MB-435. Cancer Res., 56: 5246-5252, 1996.
19. Rettenmeier, C. W., Chen, J. H., Roussel, M. F., and Sherr, C. J. The product of the c-fins proto-oncogene: a glycoprotein with associated tyrosine kinase activity. Science (Washington DC), 228: 320-322, 1985.
20. Sherr, C. J. The fins oncogene. Biochim. Biophys. Acta, 948: 225-243, 1988.
21. Woolford, J. V., Rothwell, V., and Rohrschneider, L. R. Characterization of the human c-fms gene product and its expression in cells of the monocyte-macrophage lineage. Mol. Cell. Biol., 5: 3458-3466, 1985.
22. Sariban, E., Mitchell, T., and Kufe, D. Expression of the c-fms proto-oncogene during human monocytic differentiation. Nature (Lond.), 316: 64-66, 1985.
23. Pollard, J. W., Bartocci, A., Arceci, R., Orlovsky, A., Ladner, M. B., and Stanley, E. R. Apparent role of the macrophage growth factor CSF-1 in placental development. Nature (Lond.), 330: 484-486, 1987.
24. Daiter, E., Pampfer, S., Yeung, Y. G., Barad, D., Stanley, E. R. and Pollard, J. W. Expression of colony-stimulating factor-1 in the human uterus and placenta. J. Clin. Endocrinol. Metabol., 74: 850-858, 1992.
25. Pollard, J. W., and Henninghausen, L. Colony stimulating factor 1 is required for mammary gland development during pregnancy. Proc. Natl. Acad. Sci. USA, 91: 9312-9316, 1994.
26. Sapi, E., Flick, M. B., Rodov, S., Carter, D., and Kacinski, B. M. Expression of CSF-1 and CSF-1 receptor by normal lactating mammary epithelial cell. J. Soc. Gynecol. Invest., 5: 94-101, 1998.
27. Sapi, E., and Kacinski, B. M. The role of CSF-1 in normal and neoplastic breast physiology. Soc. Exp. Biol. Med., 220: 1-8, 1999.
28. Kacinski, B. M., Scata, K. A., Carter, D., Yee, L. D., Sapi, E., King, B. L., Chambers, S. K., Jones, M. A., Pirro, M. H., Stanley, E. R., and Rohrschneider, L. R. FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene, 6: 941-952, 1991.
29. Kacinski, B. M., Carter, D., Mittal, K., Kohorn, E. I., Bloodgood, R. S., Donahue, J., Donofrio, L., Edwards, R., Schwartz, P. E., Chambers, J. T., and Chambers, S. K. High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas. Int. J. Radiat. Oncol. Biol. Phys., 15: 823-829, 1988.
30. Baiocchi, G., Kavanagh, J. J., Talpaz, M., Wharton, J. T., Gutterman, J. U., and Kurrock, R. Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. Cancer (Phila.), 67: 990-996, 1991.
31. Scholl, S. M., Crocker, P., Tang, R., Pouillart, P., and Pollard, J. W. Is colony-stimulating factor-1 a key mediator of breast cancer invasion and metastasis. Mol. Carcinog., 7: 207-211, 1993.
32. Maher, M. G., Sapi, E., Turner, B. C., Gumbs, A., Perotta, P. L., Carter, D., Kacinski, B. M., and Haffty, B. G. Prognostic significance of colony-stimulating factor receptor expression in ipsilateral breast cancer recurrence. Clin. Cancer Res., 4: 1851-1856, 1998.
33. Sapi, E., Flick, M. B., Rodov, S., Gilmore-Hebert, M., Kelley, M., Rockwell, S., and Kacinski, B. M. Independent regulation of invasion and anchorage-independent growth by different autophosphorylation sites of the macrophage colony-stimulating factor 1 receptor. Cancer Res., 56: 5704-5712, 1996.
34. Daiter, E., and Pollard, J. W. Colony stimulating factor-1 (CSF-1) in pregnancy. Reprod. Med. Rev., 1: 83-87, 1992.
35. Sapi, E., Flick, M. B., Gilmore-Hebert, M., Rodov, S., and Kacinski, B. M. Transcriptional regulation of the c-fms (CSF-1R) proto-oncogene in human breast carcinoma cells by glucocorticoids. Oncogene, 10: 529-542, 1995.
36. Roberts, W. M., Shapiro, L. H., Ashmun, R. A., and Look, T. A. Transcription of the colony stimulating factors-1 receptor gene is regulated by separate tissue-specific promoters. Blood, 79: 586-593, 1992.
37. Coussens, L., Van Beveren, C., Smith, D., Chen, E., Mitchell, R. L., Isacke, C. M., Verma, I. M., and Ullrich, A. Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus. Nature (Lond.), 320: 277-280, 1986.
38. Visvader, J., and Verma, I. M. Differential transcription of exon 1 of the human c-fms gene in placental trophoblasts and monocytes. Mol. Cell. Biol., 9: 1336-1341, 1989.
39. Schreiber, E., Matthias, P., MŸller, M. M., and Schaffner, W. Rapid detection of octamer binding proteins with "mini-extracts" prepared from a small number of cells. Nucleic Acids Res., 17: 6419-6420, 1989.
40. Tabor, S., Struhl, K., Scharf, S. J., and Gelfand, D. H. DNA-dependent DNA polymerases. In: F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (eds.), Current Protocols in Molecular Biology, Vol. 1, pp. 3.5.1-3.5.15. New York: John Wiley & Sons, Inc., 1990.
41. Pichersky, E. DNA sequencing by the chemical method. In: A. Harwood (ed.), Methods in Molecular Biology. Basic DNA and RNA Protocols, Vol. 58, pp. 447-451. Totowa, NJ: Humana Press, Inc., 1996.
42. Eustice, D. C., Feldman, P. A., Colberg-Poley, A. M., Buckery, R. M., and Neubauer, R. H. Sensitive method for the detection of β-galactosidase in transfected mammalian cells. Biotechniques, 11: 739-743, 1991.
43. Apfel, C., Bauer, F., Crettaz, M., Forni, L., Kamber, M., Kaufmann, F., LeMotte, P., Pirson, W., and Klaus, M. A retinoic acid receptor α antagonist selectively counteracts retinoic acid effects. Proc. Natl. Acad. Sci. USA, 89: 7129-7133, 1992.
44. Toma, S., Isnardi, L., Raffo, P., Riccardi, L., Dastoli, G., Apfel, C., LeMotte P., and Bollag, W. RARα antagonist RO 41-5253 inhibits proliferation and induces apoptosis in breast-cancer cell lines. Int. J. Cancer, 78: 86-94, 1998.
45. Laniel, M-A., and Gueri, S. L. Improving sensitivity of the electrophoretic mobility shift assay by restricting tissue phosphatase activity. Biotechniques, 24: 964-975, 1998.
46. Filderman, A., Bruckner, A., Kacinski, B. M., Deng, M., Hines, G., and Remold, H. Macrophage colony-stimulating factor (CSF-1) enhances invasiveness in CSF-1 receptor (CSF-1R)-positive cancer cell lines. Cancer Res., 52: 3661-3669, 1992.
47. Webber, M. M., and Waghray, A. Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid. Clin. Cancer Res., 1: 755-761, 1995.
48. Jacob, K., Wach, F., Holzapfel, U., Hein, R., Lengyel, E., Buettner, R., and Bosserhoff, A. K. In vitro modulation of human melanoma cell invasion and proliferation by all-trans-retinoic acid. Melanoma Res., 8: 211-219, 1998.
49. Nakajima, M., Lotan, D., Baig, M. M., Carralero, R. M., Wood, W. R., Hendrix, M. J., and Lotan, R. Inhibition by retinoic acid of type IV collagenolysis and invasion through reconstituted basement membrane by metastatic rat mammary adenocarcinoma cells. Cancer Res., 49: 1698-1706, 1989.
50. Tiberio, A. Farina, A. R., Tacconelli, A., Cappabianca, L., Gulino, A., and Mackay, A. R. Retinoic acid-enhanced invasion through reconstituted basement membrane by human SK-N-SH neuroblastoma cells involves membrane-associated tissue-type plasminogen activator. Int. J. Cancer, 73: 740-748, 1997.
51. Bracke, M. E., Van Larebeke, N. A., Vyncke, B. M., and Mareel, M. M. Retinoic acid modulates both invasion and plasma membrane ruffling of MCF-7 human mammary carcinoma cells in vitro. Br. J. Cancer, 63: 867-872, 1991.
52. Angel, P., and Karin, M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta, 1072: 129-157, 1991.
53. Sommers, C. L., Skerker, J. M., Chrysogelos, S. A., Bosseler, M., and Gelmann, E. P. Regulation of vimentin gene transcription in human breast cancer cell lines. Cell Growth Differ., 5: 839-846, 1994.
54. Arts, J., Herr, I., Lansink, M., Angel, P., and Kooistra, T. Cell-type specific DNA-protein interactions at the tissue-type plasminogen activator promoter in human endothelial and HeLa cells in vivo and in vitro. Nucleic Acids Res., 25: 311-317, 1997.
55. Mira-Y-Lopez, R., Jaramillo, S., and Jing, Y. Synergistic transcriptional activation of the mouse urokinase plasminogen activator (uPA) gene and of its enhancer activator protein 1 (AP1) site by cAMP and retinoic acid. Biochem. J., 331: 909-916, 1998.
56. Saiga, T., Wierenga, D. E., Levenbook, I., and Petricciani, J. C. Comparison of the colony forming ability and invasive potential of six primate cell lines treated with retinoic acid. Invest. New Drugs, 4: 25-29, 1986.
57. Darro, F., Cahen, P., Vianna, A., Decaestecker, C., Nogaret, J. M., Leblond, B., Chaboteaux, C., Ramos, C., Petein, M., Budel, V., Schoofs, A., Pourrias, B., and Kiss, R. Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen. Breast Cancer Res. Treat., 51: 39-55, 1998.
58. Castaigne, S., Chomienne, C., Daniel, M. T., Ballerini, P., Berger, R., Fenaur, P., and Degos, L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. Blood, 76: 1704-1709, 1990.
59. Benner, S. E., Pajak, T. F., Lippman, S. M., Earley, C., and Hong, W. K. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J. Natl. Cancer Inst., 86: 140-141, 1994.
60. Costa, A., De Palo, G., Decensi, A., Formelli, F., Chiesa, F., Nava, M., Camerini, T., Marubini, E., and Veronesi, U. Retinoids in cancer and chemoprevention. Clinical trials with the synthetic analogue fenretidine. Ann. N. Y. Acad. Sci., 768: 148-162, 1995.
61. Budd, G. T., Adamson, P. C., Gupta, M., Homayoun, P., Sandstrom, S. K., Murphy, R. F., McLain, D., Tuason, L., Peereboom, D., Bukowski, R. M., and Ganapathi, R. Phase I/II trial of all-trans-retinoic acid and tamoxifen in patients with advanced breast cancer. Clin. Cancer Res., 4: 635-642, 1998.
62. Gagne, D., Pous, M., and Philiberts, D. RU486: a potent antiglucocorticoid in vitro and in vivo. Steroid Biochem., 23: 247-251, 1985.
63. Klijn, J. G. M., DeJong, F. H., Bakker, G. H., Lamberts, S. W. J., Rodenburg, C. J., and Alexieva-Figush, J. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res., 49: 2851-2856, 1989.